Deep Learning from Histology can Broaden Drug Development
- Immunotherapy combinations are ripe for dissection by DL powered analysis of the Tumor Microenvironment
- DL assessment of target expression is key for subsets of Large Molecule Therapeutics
- Advances in digital path have paved the way for a broad rollout of DL driven biomarker